The science
The serum's single active is dehydrolatanoprost, a dehydrated derivative of latanoprost and therefore a prostaglandin F2-alpha analogue, the class whose lash-growing side effect in glaucoma patients gave rise to prescription lash treatment and, later, to eyebrow use. Prostaglandin analogues act on receptors in the hair follicle to extend anagen, the growth phase, and to convert a larger fraction of follicles from rest to growth, producing fuller, longer and darker hair while application continues and reverting over subsequent cycles when it stops. For brows specifically, the reference evidence is Carruthers and colleagues' 2016 multicentre, double-masked trial in Dermatologic Surgery, which randomised adult men and women with eyebrow hypotrichosis to bimatoprost 0.03 percent twice daily, once daily or vehicle twice daily for seven months; at month seven the proportion of subjects with improved overall eyebrow fullness was significantly higher in both bimatoprost groups than with vehicle, improvements in fullness and darkness appeared from months two and one respectively, subject satisfaction exceeded vehicle from month two onward, treatment-emergent adverse events were similar across groups at around 35 to 42 percent, and no skin or iris hyperpigmentation or conjunctival hyperaemia occurred. Dehydrolatanoprost is a distinct molecule marketed as a cosmetic and has no published trial; Obagi's 2022 twelve-week blinded study, reporting improved brow fill in all participants and improved density and thickness in most at eight weeks, is held on file without a published subject count. The class mechanism, the onset at four to eight weeks and the side-effect pattern in user reports are nonetheless consistent with the prescription literature.
The class's adverse effects in the lid and brow region are documented: erythema and pruritus at the application site, hyperpigmentation of periorbital skin along the treated line, hypertrichosis where the product migrates, and, for prostaglandin eye drops in light irises, permanent iris darkening; the absence of pigmentation in the seven-month bimatoprost brow trial suggests that dose and confinement to the hair-bearing skin are the main determinants, which is consistent with user reports that a thin stroke kept within the brow reduces darkening. The remaining ingredients are vehicle and conditioning: biotin has no evidence for topical hair growth and is listed above the active by concentration, phenethyl caffeate is a caffeic acid ester with in-vitro anti-inflammatory activity plausibly included to reduce irritation, sodium hyaluronate and panthenol hydrate the skin and improve hair flexibility, C12-15 alkyl benzoate provides slip, and alcohol and caprylyl glycol aid drying and preservation. The serum's efficacy therefore rests on one drug-class ingredient at an undisclosed concentration, presented within a vitamin-led complex whose other components contribute comfort rather than growth.
References 1 ShowHide
- Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis — Dermatologic Surgery (2016)